Fortress Biotech, Inc. (FBIOP)
FBIOPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$13.95
+0.2250 (+1.64%) today
Closed, Nov 18, 4:00 PM ET
- Market cap
- $463.96m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.50 to $21.43
- Average volume
- –
- Previous close
- $13.73
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $16.08m | $16.04m | $18.72m | $19.16m |
| Gross profit | $10.64m | $9.82m | $12.57m | $13.27m |
| Operating income | -$4.79m | -$7.74m | -$10.01m | -$7.19m |
| Net income | -$3.94m | $110.37m | -$468.0k | -$5.84m |
Last four quarters: revenue $69.99m, margin 143.1%, free cash flow –
News
2 latestThe company
Fortress Biotech, Inc. ('Fortress') is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- fortressbiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.